Study on Amino Acid Uptake in Brain Tumors
Recruitment status was Active, not recruiting
The purpose of this study is to determine the uptake of the amino acid O-(2-[F-18]Fluorethyl)-L-tyrosin (FET) in human brain tumors using positron emission tomography. A comparison to MRI and histopathological samples is used.
Drug: O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)|
- Histological samples where available
- CD98 staining where available
- Clinical follow-up for at least one year
|Study Start Date:||January 2004|
Radioactively labelled amino acids have been used for years to delineate primary brain tumors and for the early detection of tumor recurrence. Positron emission tomography studies indicate that the extent of amino acid uptake correlates to the true histological extent of gliomas. Recently a fluorine-18 labelled amino acid has been introduced (O-(2-[F-18]Fluorethyl)-L-tyrosin (FET)), which is suitable for routine use in brain tumor patients. There is evidence that this amino acid is transported into brain and brain tumors by the amino acid transport of the L-type. The cDNA of this L-transporter has recently been cloned and has been shown to be identical to the light chain of the 4F2-antigen (CD98), which has previously been described as marker of cell growth and proliferation.
The heavy chain of this heterodimer is known to modulate integrins which are thought to play a fundamental role in glioma invasion.
Besides the evaluation of the diagnostic capability of FET in brain tumors, a comparison of FET uptake in vivo and CD98 expression ex-vivo is performed with tissue slices as available after routine surgery in glioma patients.
|Department of Nuclear Medicine, University Hospital Muenster|
|Muenster, NRW, Germany, D-48149|
|Principal Investigator:||Matthias Weckesser, MD||Department of Nuclear Medicine, University Hospital Muenster|